AnalystsNavin JacobNavin Jacob's Stock Forecasts
AnalystsNavin Jacob
Sectors:
Industries:
Analyst Ranking
Top 28%
#1269 out of 4565 analysts
Average Return
+23.46%
Win Rate
78%7 out of 9
Risk vs Reward
Poor
Good
Navin Jacob's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +76.96% | $310.87 | $550.13 | 2022-09-21 - 2023-09-21 | Strong Buy |
Abbvie IncABBV | +34.77% | $80.30 | $108.22 | 2020-04-12 - 2021-04-13 | Strong Buy |
Abbvie IncABBV | +34.21% | $114.96 | $154.29 | 2021-05-11 - 2022-05-12 | Strong Buy |
Abbvie IncABBV | +25.25% | $116.89 | $146.40 | 2021-11-28 - 2022-10-31 | Strong Buy |
Abbvie IncABBV | +20.01% | $95.74 | $114.90 | 2020-06-16 - 2021-06-17 | Strong Buy |
Navin Jacob Analyst Color
Get additional color on Navin Jacob's coverage of popular stocks
Navin Jacob's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Abbvie IncABBV | 9 | Hold | $152.00 | N/A | Maintains | a year ago |
Eli Lilly & CoLLY | 2 | Strong Buy | $363.00 | N/A | Upgrades | 2 years ago |
Royalty Pharma PLCRPRX | 1 | Strong Buy | $51.00 | N/A | Upgrades | 3 years ago |
Intercept Pharmaceuticals IncICPT | 1 | Hold | $57.00 | N/A | Downgrades | 4 years ago |
Merck & Co IncMRK | 1 | Strong Buy | $92.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.